about
Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis: Observational Data from Southern Sweden.Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy: a population-based regional cohort study from southern Sweden.A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate FailureWhat PASSes for good? Experience-based Swedish and hypothetical British EuroQol 5-Dimensions preference sets yield markedly different point estimates and patient acceptable symptom state cut-off values in chronic arthritis patients on TNF blockade.Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial.Patient-Reported Outcomes Are More Important Than Objective Inflammatory Markers for Sick Leave in Biologics-Treated Patients With Rheumatoid ArthritisIrritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis: results from the SPARTAKUS cohortSerum Biomarkers for Prediction of Response to Methotrexate Monotherapy in Early Rheumatoid Arthritis: Results from the SWEFOT TrialResponse to: 'response to: irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?' by Proft et alConsiderations for Evaluating and Recommending Worker Productivity Outcome Measures: An Update from the OMERACT Worker Productivity Group
P50
Q31104809-25A995CB-C458-464F-BD8A-C9AD4EE5C2D0Q36477447-B60B252B-3CA1-4CBE-AD08-C57EA05CFFE5Q36577396-3FDEE81B-4B1E-48FA-BF30-41B8B13BB2D9Q36596599-B3D6D11C-0F3A-418A-9E44-E23A6345E46DQ39033928-E72CEB07-0495-4215-9EB9-2BE37CD82059Q39088676-AB38BC57-5DFD-47F4-AEC6-81F83D06A782Q39879833-11916CE8-9C58-4DB3-8045-FD0C8DA64493Q39888893-8B2861B1-BAEA-4295-AFA0-16E295775D19Q89048107-6F8F90F6-7037-4DF7-B26A-73E5F499D937Q90493582-804D7B5F-3176-414B-903A-613DC2340B56Q91072605-38AB6FE2-D629-43BE-A158-79B2CDCE7716Q91312025-E5C6ABF3-29D5-414D-B405-47D21D17D4F6Q92355968-EBF262EC-F354-4D52-B2CF-3AAA841A2286Q92766002-D6A880F3-6F70-4082-9114-069DFFBB8A59
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-4915-2924
@en
name
Johan A Karlsson
@ast
Johan A Karlsson
@en
Johan A Karlsson
@nl
type
label
Johan A Karlsson
@ast
Johan A Karlsson
@en
Johan A Karlsson
@nl
prefLabel
Johan A Karlsson
@ast
Johan A Karlsson
@en
Johan A Karlsson
@nl
P106
P31
P496
0000-0002-4915-2924